EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea

Ashok K Tuteja iD, Daniel T Leung, John C Fang, Nicholas J Talley iD, Gregory J Stoddard

Neurogastroenterology & Motility · 2024

DOI: 10.1111/nmo.14889 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, 2024. Verfasst von Ashok K Tuteja und 4 weiteren Autor:innen. Beteiligte Einrichtung: George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Mesalamine, Diarrhea, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported in part by grant from Shire Pharmaceuticals. AKT received grant support from the Department of Veterans Affairs and the Department of….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A subset of patients with irritable bowel syndrome (IBS) develop their symptoms after gastroenteritis, referred to as postinfectious IBS (PI‐IBS). PI‐IBS is associated with low‐grade intestinal inflammation. Previous studies have evaluated mesalamine, an anti‐inflammatory drug, in patients with IBS. We evaluated the efficacy of long‐acting mesalamine in patients with PI‐IBS.

Methods

Sixty‐one patients who developed diarrhea‐predominant IBS (IBS‐D) after gastroenteritis were randomized to receive either 2.4 g of long‐acting mesalamine or placebo daily for 8‐weeks. The symptoms assessed were abdominal pain, bloating, stool frequency, stool consistency, severity of diarrhea and constipation, satisfaction with bowel habits, and IBS affecting or interfering with life. Quality‐of‐life (QOL) was assessed using the IBS‐QOL questionnaire. The prespecified primary outcome variable was the overall bowel symptom score (BSS) after 8‐weeks of treatment. Effect sizes were expressed as standardized mean differences (Cohen's d ).

Results

Fifty‐four patients completed the 8‐week treatment ( n = 28 mesalamine, n = 26 placebo), 49 (91%) were male, and age range 23–71 years (mean ± SD 43 ± 13). Mesalamine demonstrated superior efficacy compared to placebo on the primary outcome variable, overall BSS (Cohen's d = 0.57, p = 0.042). Mesalamine was also superior for the secondary outcome of how much IBS affects your life in general ( d = 0.72, p = 0.01). For the secondary outcomes of IBS symptoms, 7 of the 7 symptoms had trends of mesalamine superiority. For the secondary outcomes of IBS‐QOL subscales, 8 of 9 had trends of mesalamine superiority.

Conclusion

In patients with PI‐IBS, long‐acting mesalamine demonstrated to be effective in reducing IBS symptoms and improving QOL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeMesalamineDiarrheaAnti-Inflammatory Agents, Non-SteroidalQuality of LifeHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedTreatment OutcomeGastroenteritisAgedDelayed-Action PreparationsYoung Adult

Stichwörter der Autor:innen

diarrheairritable bowel syndromemesalamine

Substanzen

MesalamineAnti-Inflammatory Agents, Non-SteroidalDelayed-Action Preparations

Autor:innen und Institutionen

  • George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
  • Divisions of Gastroenterology, University of Utah, Salt Lake City, Utah, USA.
  • Infectious Diseases, University of Utah, Salt Lake City, Utah, USA.
  • University of Newcastle, Callaghan, New South Wales, Australia.
  • Epidemiology, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Ashok K Tuteja, Nicholas J Talley

Förderung

  • This study was supported in part by grant from Shire Pharmaceuticals. AKT received grant support from the Department of Veterans Affairs and the Department of…

Zitieren

APA

Tuteja, A. K., Leung, D. T., Fang, J. C., Talley, N. J., & Stoddard, G. J. (2024). Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14889

Vancouver

Tuteja AK, Leung DT, Fang JC, Talley NJ, Stoddard GJ. Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14889

BibTeX
@article{Tuteja2024,
  author = {Tuteja, Ashok K and Leung, Daniel T and Fang, John C and Talley, Nicholas J and Stoddard, Gregory J},
  title = {Randomized double‐blind placebo‐controlled study to evaluate the effect of long‐acting mesalamine on postinfectious irritable bowel syndrome with diarrhea},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  doi = {10.1111/nmo.14889}
}
Kostenlos starten →